Abstract
To evaluate the incremental life-years (LY) and quality-adjusted life years (QALY) of avelumab in combination with axitinib compared with sunitinib and pazopanib in the first-line treatment of advanced renal cell carcinoma (aRCC) in patients with intermediate or poor risk and of temsirolimus in patients with poor risk in Portugal.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
